ANXA5 and thrombophilia: She then continued her follow-up in the high-risk obstetrics appointment at Maternidade Bissaya Barreto. In the context of this consultation, she underwent thrombophilia studies which revealed the presence of double heterozygosity for Factor V Leiden and for PRT20210G/A and the presence of ANXA5 (M1/M2) and PAI-4G/4G. In a multidisciplinary meeting, it was decided to increase the enoxaparin dose to 70 mg twice a day, with control through the determination of the anti-Xa value. During the course of the pregnancy, she developed severe cholestasis and was medicated with ursodeoxycholic acid.